• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vildagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vildagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Biologic medications as second-line therapy for rheumatoid arthritis]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocriplasmin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linaclotide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-09 (vandetanib)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-10 (pertuzumab)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisdexamfetamine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-03 (sitagliptin/metformin)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-16 (vildagliptin)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-17 (vildagliptin/metformin)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ponatinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vismodegib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "COPD"]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal, as well as extraction of new and relevant recommendations, for the DMP "asthma"]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regorafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Eylea) extension of approval - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Teriflunomide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Prevention of nephropathy by iodinated contrast media during a radiological intervention]
2013 National Institute for Health and Care Excellence (NICE) Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract. NICE technology appraisal guidance 272
2013 National Institute for Health and Care Excellence (NICE) Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal). NICE technology appraisal guidance 273
2013 National Institute for Health and Care Excellence (NICE) Ranibizumab for treating diabetic macular oedema. NICE technology appraisal guidance 274
2013 National Institute for Health and Care Excellence (NICE) Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. NICE technology appraisal guidance 275
2013 National Institute for Health and Care Excellence (NICE) Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis. NICE technology appraisal guidance 276
2013 National Institute for Health and Care Excellence (NICE) Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal). NICE technology appraisal guidance 277
2013 National Institute for Health and Care Excellence (NICE) Omalizumab for treating severe persistent allergic asthma. NICE technology appraisal guidance 278
2013 National Institute for Health and Care Excellence (NICE) Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures. NICE technology appraisal guidance 279
2013 National Institute for Health and Care Excellence (NICE) Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. NICE technology appraisal guidance 283
2013 National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE technology appraisal guidance 284
2013 National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. NICE technology appraisal guidance 285
2013 National Institute for Health and Care Excellence (NICE) Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal). NICE technology appraisal guidance 286
2013 National Institute for Health and Care Excellence (NICE) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
2013 National Institute for Health and Care Excellence (NICE) Dapagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 288
2013 National Institute for Health and Care Excellence (NICE) Mirabegron for treating symptoms of overactive bladder. NICE technology appraisal guidance 290
2013 National Institute for Health and Care Excellence (NICE) Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. NICE technology appraisal guidance 292
2013 National Institute for Health and Care Excellence (NICE) Eltrombopag for treating chronic immune thrombocytopenia. NICE technology appraisal guidance 293
2013 National Institute for Health and Care Excellence (NICE) Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance 294
2013 National Institute for Health and Care Excellence (NICE) Ocriplasmin for treating vitreomacular traction. NICE technology appraisal guidance 297
2013 National Institute for Health and Care Excellence (NICE) Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. NICE technology appraisal guidance 298
2013 National Institute for Health and Care Excellence (NICE) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. NICE technology appraisal guidance 300
2013 National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy. NICE technology appraisal guidance 301
2013 National Institute for Health and Care Excellence (NICE) Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal). NICE technology appraisal guidance 302
2013 National Institute for Health and Care Excellence (NICE) Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events. NICE interventional procedures guidance 472
2013 National Institute for Health and Care Excellence (NICE) Uterine artery embolisation for treating adenomyosis. NICE interventional procedures guidance 473
2013 National Institute for Health and Care Excellence (NICE) Negative pressure wound therapy for the open abdomen. NICE interventional procedures guidance 467
2013 National Institute for Health and Care Excellence (NICE) Phrenic nerve transfer in brachial plexus injury. NICE interventional procedures guidance 468
2013 National Institute for Health and Care Excellence (NICE) Implantation of a duodenal–jejunal bypass sleeve for managing obesity. NICE interventional procedures guidance 471
2013 National Institute for Health and Care Excellence (NICE) Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia. NICE interventional procedures guidance 466
2013 National Institute for Health and Care Excellence (NICE) Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. NICE interventional procedures guidance 461
2013 National Institute for Health and Care Excellence (NICE) Translaryngeal tracheostomy. NICE interventional procedures guidance 462
2013 National Institute for Health and Care Excellence (NICE) Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. NICE interventional procedures guidance 457
2013 National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy for primary hepatocellular carcinoma. NICE interventional procedures guidance 460
2013 National Institute for Health and Care Excellence (NICE) Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction. NICE interventional procedures guidance 449
2013 National Institute for Health and Care Excellence (NICE) Occipital nerve stimulation for intractable chronic migraine. NICE interventional procedures guidance 452
2013 National Institute for Health and Care Excellence (NICE) Corneal inlay implantation for correction of presbyopia. NICE interventional procedures guidance 455
2013 National Institute for Health and Care Excellence (NICE) Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. NICE interventional procedures guidance 446
2013 National Institute for Health and Care Excellence (NICE) Insertion of endobronchial valves for persistent air leaks. NICE interventional procedures guidance 448
2013 National Institute for Health and Care Excellence (NICE) Percutaneous electrical nerve stimulation for refractory neuropathic pain. NICE interventional procedures guidance 450
2013 National Institute for Health and Care Excellence (NICE) Peripheral nerve-field stimulation for chronic low back pain. NICE interventional procedures guidance 451
2013 National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating primary lung cancer and metastases in the lung. NICE interventional procedures guidance 441
2013 National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating renal cancer. NICE interventional procedures guidance 443
2013 National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating liver metastases. NICE interventional procedures guidance 445
2013 National Institute for Health and Care Excellence (NICE) Ultrasound-guided foam sclerotherapy for varicose veins. NICE interventional procedures guidance 440
2013 National Institute for Health and Care Excellence (NICE) Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. NICE interventional procedures guidance 436
2013 National Institute for Health and Care Excellence (NICE) Autologous blood injection for plantar fasciitis. NICE interventional procedures guidance 437
2013 National Institute for Health and Care Excellence (NICE) Autologous blood injection for tendinopathy. NICE interventional procedures guidance 438
2013 National Institute for Health and Care Excellence (NICE) Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy. NICE interventional procedures guidance 439
2013 National Institute for Health and Care Excellence (NICE) EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing. NICE medical technologies guidance 12
2013 National Institute for Health and Care Excellence (NICE) Ambu aScope4 Broncho for use in unexpected difficult airways. NICE medical technologies guidance 14
2013 National Institute for Health and Care Excellence (NICE) E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta. NICE medical technologies guidance 16
2013 National Institute for Health and Care Excellence (NICE) Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. NICE diagnostics guidance 11
2013 National Institute for Health and Care Excellence (NICE) EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. NICE diagnostics guidance 9
2013 National Institute for Health and Care Excellence (NICE) Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. NICE diagnostics guidance 8
2013 Canary Health Service [Cost-effectiveness of neonatal screening for biotinidase deficiency]
2013 Canary Health Service [Cost-effectiveness of neonatal screening for congenital adrenal hyperplasia]
2013 Canary Health Service [Cost-effectiveness of neonatal screening for classical galactosemia]
2013 Canary Health Service [Cost-effectiveness of neonatal screening for tyrosemia type I]
2013 Canary Health Service [Effectiveness and safety of biodegradable tracheobronchial prostheses]
2013 Canary Health Service [Deep brain stimulation in neurological and psychiatric disorders]
2013 Canary Health Service [Manual with evaluation and validation criteria for shared decision-making tools]
2013 Canary Health Service [Cost-effectiveness review of physiotherapy interventions in knee osteoarthritis]
2013 Canary Health Service [Endobronchial valves: effectiveness, safety, and cost-effectiveness]
2013 Canary Health Service [Cost-effectiveness analysis of microarrays for prenatal diagnosis of genetic aberrations in Spain]
2013 Canary Health Service [Cost-effectiveness of electroconvulsive therapy in the treatment of depression. Systematic review and economic evaluation]
2013 Canary Health Service [Cost-effectiveness of newborn screening for sickle cell anemia]
2013 Canary Health Service [Indications for transcranial magnetic stimulation: major depressive disorder and other disorders]
2013 Canary Health Service [Alternative systems to conventional holter for ambulatory study of cardiac arrhythmias (update)]
2013 Health Information and Quality Authority (HIQA) A series of health technology assessments (HTAs) of clinical referral or treatment thresholds for scheduled surgical procedures. Phase I
2013 Health Information and Quality Authority (HIQA) A series of health technology assessments (HTAs) of clinical referral or treatment thresholds for scheduled surgical procedures. Phase II
2012 Norwegian Knowledge Centre for the Health Services (NOKC) [Prevention of allergy among children]
2012 Agency for Healthcare Research and Quality (AHRQ) Framework for considering study designs for future research needs